-
The FDA has approved a new combination product for the treatment of type 2 diabetes mellitus. Sitagliptin, the recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor is combined with metformin in two different dose configurations. Sitagliptin/metformin is marketed by Merck & Co., Inc as Janumet.
-
-
Marcolina ST. Nonpharmacologic management of migraines. Altern Med Alert 2007;10(6):61-65.
-
O'Mathuna DP. Antioxidant vitamins, immunity, and endurance exercise. Altern Med Alert 2007;10(6):66-69.
-
Greenfield RH. Tea time will never be the same again: Tea and milk. Altern Med Alert 2007;10(6):70-71. Greenfield RH. Adults, herbs, and evidence-based medicine. Altern Med Alert 2007;10(6):71-72. Greenfield RH. One does not equal twoCinnamon and diabetes mellitus. Altern Med Alert 2007;10(6):72.
-
National Institutes of Neurological Disorders and Stroke. Migraine headaches. Altern Med Alert 2007;10(suppl 6):S1-S2.
-
-
A simple questionnaire can identify individuals at risk for chronic kidney disease.
-
A new class of drug has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides.
-
Persons who do not suffer hyperhidrosis (HID) may be surprised to learn that it has been associated with both occupational and physical impairment, as well as limitations in social interaction.
